The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical studies with neratinib in triple-negative breast cancer.
Maeve Mullooly
No relevant relationships to disclose
Neil A. O'Brien
No relevant relationships to disclose
Dylan Conklin
No relevant relationships to disclose
Richard S. Finn
No relevant relationships to disclose
Dennis J. Slamon
No relevant relationships to disclose
John Crown
No relevant relationships to disclose
Norma O'Donovan
No relevant relationships to disclose
Patricia M. McGowan
No relevant relationships to disclose
Michael J. Duffy
No relevant relationships to disclose